{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T03:05:30Z","timestamp":1768273530855,"version":"3.49.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1097\/aco.0000000000000614","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T02:34:33Z","timestamp":1527734073000},"page":"423-430","source":"Crossref","is-referenced-by-count":10,"title":["Challenges of bringing a new sedative to market!"],"prefix":"10.1097","volume":"31","author":[{"given":"John W.","family":"Sear","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-7-20210129","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1097\/00000542-200611000-00027","article-title":"Reports of death with use of propofol (Diprivan) for nonprocedural (long-term) sedation and literature review\u2019","volume":"105","author":"Wysowski","year":"2006","journal-title":"Anesthesiology"},{"key":"R2-7-20210129","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/01.anes.0000265151.78943.af","article-title":"Pharmacokinetics and pharmacodynamics of propofol microemulsion and lipid emulsion after an intravenous bolus and variable rate infusions","volume":"106","author":"Kim","year":"2007","journal-title":"Anesthesiology"},{"key":"R3-7-20210129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijpharm.2004.02.028","article-title":"Evaluation of new propofol aqueous solutions for intravenous anesthesia","volume":"278","author":"Trapani","year":"2004","journal-title":"Int J Pharm"},{"key":"R4-7-20210129","first-page":"920","article-title":"The effect of a cyclodextrin vehicle on the cardiovascular profile of propofol in rats","volume":"82","author":"Bielen","year":"1996","journal-title":"Anesth Analg"},{"key":"R5-7-20210129","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11095-007-9471-5","article-title":"Novel lipid and preservative-free propofol formulation: properties and pharmacodynamics","volume":"25","author":"Ravenelle","year":"2008","journal-title":"Pharm Res"},{"key":"R6-7-20210129","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/bja\/aen147","article-title":"Anaesthetic properties of propofol polymeric micelle: a novel water soluble propofol formulation","volume":"101","author":"Ravenelle","year":"2008","journal-title":"Br J Anaesthesia"},{"key":"R7-7-20210129","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1097\/00000539-200211000-00034","article-title":"Propofol phosphate. A water-soluble propofol prodrug: in vivo evaluation","volume":"95","author":"Banaszczyk","year":"2002","journal-title":"Anesth Analg"},{"key":"R8-7-20210129","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0928-0987(03)00161-1","article-title":"Highly water-soluble derivatives of the anaesthetic agent propofol: in vitro and in vivo evaluation of cyclic amino acid esters","volume":"20","author":"Altomare","year":"2003","journal-title":"Eur J Pharm Sci"},{"key":"R12-7-20210129","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1248\/cpb.55.1682","article-title":"Novel water-soluble sedative-hypnotic agents: isoindolin-1-one derivatives","volume":"55","author":"Kanamitsu","year":"2007","journal-title":"Chem Pharm Bull (Tokyo"},{"key":"R13-7-20210129","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-1-4419-5692-7_23","article-title":"Effect of JM-1232(\u2212), a new sedative on central respiratory activity in newborn rats","volume":"669","author":"Kuribayashi","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"R14-7-20210129","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/ALN.0b013e318242b2af","article-title":"First human administration of MR04A3: a novel water-soluble nonbenzodiazepine sedative","volume":"116","author":"Sneyd","year":"2012","journal-title":"Anesthesiology"},{"key":"R15-7-20210129","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1097\/ALN.0b013e31825685a6","article-title":"AZD-3043: a novel, metabolically labile sedative-hypnotic agent with rapid and predictable emergence from hypnosis","volume":"116","author":"Egan","year":"2012","journal-title":"Anesthesiology"},{"key":"R16-7-20210129","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1213\/ANE.0000000000000831","article-title":"First human study of the investigational sedative and anesthetic drug AZD3043: a dose-escalation trial to assess the safety, pharmacokinetics, and efficacy of a 30-minute infusion in healthy male volunteers","volume":"121","author":"Kalman","year":"2015","journal-title":"Anesth Analg"},{"key":"R17-7-20210129","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1213\/ANE.0000000000000804","article-title":"A bolus and bolus followed by infusion study of AZD3043, an investigational intravenous drug for sedation and anesthesia: safety and pharmacodynamics in healthy male and female volunteers","volume":"121","author":"Norberg","year":"2015","journal-title":"Anesth Analg"},{"key":"R18-7-20210129","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1213\/ANE.0000000000000814","article-title":"A recirculatory model for pharmacokinetics and the effects on bispectral index after intravenous infusion of the sedative and anesthetic AZD3043 in healthy volunteers","volume":"121","author":"Bj\u00f6rnsson","year":"2015","journal-title":"Anesth Analg"},{"key":"R19-7-20210129","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/ALN.0b013e3181ae63d1","article-title":"Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression","volume":"111","author":"Cotton","year":"2009","journal-title":"Anesthesiology"},{"key":"R20-7-20210129","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/ALN.0b013e3181cf40ed","article-title":"Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function","volume":"112","author":"Cotten","year":"2010","journal-title":"Anesthesiology"},{"key":"R21-7-20210129","doi-asserted-by":"crossref","first-page":"R20","DOI":"10.1186\/cc12494","article-title":"Adrenocortical suppression and recovery after continuous hypnotic infusion: etomidate versus its soft analogue cyclopropylmethoxycarbonyl metomidate","volume":"17","author":"Ge","year":"2012","journal-title":"Crit Care"},{"key":"R22-7-20210129","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/ALN.0000000000000416","article-title":"Advancing novel anesthetics: pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in dogs","volume":"121","author":"Campagna","year":"2014","journal-title":"Anesthesiology"},{"key":"R23-7-20210129","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/ALN.0000000000001662","article-title":"A phase 1, single-center, double-blind, placebo-controlled study in healthy subjects to assess the safety, tolerability, clinical effects, and pharmacokinetics-pharmacodynamics of intravenous cyclopropyl-methoxycarbonylmetomidate (ABP-700) after a single ascending bolus dose","volume":"127","author":"Struys","year":"2017","journal-title":"Anesthesiology"},{"key":"R24-7-20210129","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.bja.2018.01.038","article-title":"Safety and clinical effect of a 30-min intravenous infusion of cyclopropyl-methoxycarbonyl metomidate (ABP-700), a soft analogue of etomidate, in healthy subjects","volume":"120","author":"Valk","year":"2018","journal-title":"Br J Anaesth"},{"key":"R25-7-20210129","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/00000542-200510000-00011","article-title":"AQUAVAN injection, a water-soluble prodrug of propofol, as a bolus injection: a phase I dose-escalation comparison with DIPRIVAN (Part 2): Pharmacodynamics and safety","volume":"103","author":"Struys","year":"2005","journal-title":"Anesthesiology"},{"key":"R26-7-20210129","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/bcpt.12552","article-title":"Efficacy and safety of fospropofolFD-compared to propofol when given during the induction of general anaesthesia: a phase II, multicenter, randomized, parallel-group, active-controlled, double-blind, double-dummy study","volume":"119","author":"Liu","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R27-7-20210129","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2344\/0003-3006-60.4.162","article-title":"A comparison of fospropofol to midazolam for moderate sedation during outpatient dental procedures","volume":"60","author":"Yen","year":"2013","journal-title":"Anesth Prog"},{"key":"R28-7-20210129","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MCG.0b013e3181c2987e","article-title":"A randomized, double-blind, phase 3 study of fospropofol disodium for sedation during colonoscopy","volume":"44","author":"Cohen","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"R29-7-20210129","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/01.anes.0000267503.85085.c0","article-title":"CNS 7056: a novel ultra-short acting benzodiazepine","volume":"107","author":"Kilpatrick","year":"2007","journal-title":"Anesthesiology"},{"key":"R30-7-20210129","first-page":"A1610","article-title":"CNS 7056X an ultra-shortacting benzodiazepine: pharmacokinetic and pharmacodynamic study in pig","volume":"105","author":"Mutter","year":"2006","journal-title":"Anesthesiology"},{"key":"R31-7-20210129","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1213\/ANE.0b013e31823f0c28","article-title":"12 A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics","volume":"115","author":"Antonik","year":"2012","journal-title":"Anesth Analg"},{"key":"R32-7-20210129","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1213\/ANE.0b013e318241f68a","article-title":"A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation","volume":"115","author":"Wiltshire","year":"2012","journal-title":"Anesth Analg"},{"key":"R33-7-20210129","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1152\/ajplegacy.1927.82.2.294","article-title":"The physiological action of cholesterol","volume":"82","author":"Cashin","year":"1927","journal-title":"Am J Physiol"},{"key":"R34-7-20210129","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/bja\/79.4.417","article-title":"ORG 21465, a new water-soluble steroid hypnotic: more of the same or something different?","volume":"79","author":"Sear","year":"1997","journal-title":"Br J Anaesth"},{"key":"R35-7-20210129","first-page":"72","article-title":"The effects in man of infusions of Althesin with particular regard to the cardiovascular system","volume":"48","author":"Du Cailar","year":"1972","journal-title":"Postgrad Med J"},{"key":"R36-7-20210129","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2044.1975.tb00951.x","article-title":"Intravenous anaesthesia by infusion. A technique using alphaxolone\/alphadolone (Althesin)","volume":"30","author":"Savege","year":"1975","journal-title":"Anaesthesia"},{"key":"R37-7-20210129","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/bja\/51.9.867","article-title":"Dose-related haemodynamic effects of continuous infusions of Althesin in man","volume":"51","author":"Sear","year":"1979","journal-title":"Br J Anaesth"},{"key":"R38-7-20210129","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/bja\/51.9.861","article-title":"Plasma concentrations of alphaxalone during continuous infusion of Althesin","volume":"51","author":"Sear","year":"1979","journal-title":"Br J Anaesth"},{"key":"R39-7-20210129","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/bja\/55.9.849","article-title":"Baroreflex effects of Althesin infusions to supplement nitrous oxide anaesthesia in man","volume":"55","author":"Jones","year":"1983","journal-title":"Br J Anaesth"},{"key":"R40-7-20210129","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/bja\/50.12.1231","article-title":"Pharmacokinetics of Althesin \u2013 comparison with lignocaine","volume":"50","author":"Simpson","year":"1978","journal-title":"Br J Anaesth"},{"key":"R41-7-20210129","first-page":"113","article-title":"Intra-patient comparison of the kinetics of alphaxalone and alphadolone in man","volume":"1","author":"Sear","year":"1984","journal-title":"Eur J Anaesthesiol"},{"key":"R42-7-20210129","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/bja\/53.4.339","article-title":"Infusions of minaxolone to supplement nitrous oxide\u2013oxygen anaesthesia. A comparison with Althesin","volume":"53","author":"Sear","year":"1981","journal-title":"Br J Anaesth"},{"key":"R43-7-20210129","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-2885.2008.00998.x","article-title":"The pharmacokinetics and pharmacodynamics of alfaxalone in cats after single and multiple intravenous administration of Alfaxan at clinical and supraclinical doses","volume":"31","author":"Whittem","year":"2008","journal-title":"J Vet Pharmacol Ther"},{"key":"R44-7-20210129","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1467-2995.2005.00264.x","article-title":"Plasma pharmacokinetics of alfaxalone in dogs after an intravenous bolus of Alfaxan-CD RTU","volume":"33","author":"Ferr\u00e9","year":"2006","journal-title":"Vet Anaesth Analg"},{"key":"R45-7-20210129","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0378-5173(90)90114-J","article-title":"An intravenous toxicity study of 2-hydroxypropyl-\u03b2-cyclodextrin, a useful drug solubilizer, in rats and monkeys","volume":"59","author":"Brewster","year":"1990","journal-title":"Int J Pharmaceut"},{"key":"R46-7-20210129","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.neuroscience.2009.07.009","article-title":"Role of neurosteroids in regulating cell death and proliferation in the late gestation fetal brain","volume":"163","author":"Yawno","year":"2009","journal-title":"Neuroscience"},{"key":"R48-7-20210129","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1213\/01.ANE.0000066019.42467.7A","article-title":"The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol) versus propofol in a lipid formulation (Diprivan): an electroencephalographic and hemodynamic study in a porcine model","volume":"97","author":"Egan","year":"2003","journal-title":"Anesth Analg"},{"key":"R49-7-20210129","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1213\/ANE.0000000000000856","article-title":"A phase 1c trial comparing the efficacy and safety of a new aqueous formulation of alphaxalone with propofol","volume":"121","author":"Monagle","year":"2015","journal-title":"Anesth Analg"}],"container-title":["Current Opinion in Anaesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ACO.0000000000000614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T19:32:05Z","timestamp":1661369525000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001503-201808000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/aco.0000000000000614","relation":{},"ISSN":["0952-7907"],"issn-type":[{"value":"0952-7907","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}